In clinical trials, these drugs have helped participants lose an average of 15% of their weight over a year
Current NICE guidance on type 2 diabetes (NG28) and obesity management (TA875) does not include probiotics as part of standard care pathways for patients on GLP-1 receptor agonists
Instead of being a single-receptor agonist, which semaglutide (the drug in Ozempic and Wegovy) is, Mounjaro activates two receptors at the same time
BPC-157 Mechanism of Action in Research Models BPC-157 is investigated for interactions with nitric-oxide signalling, angiogenesis-related markers, fibroblast activity, extracellular matrix remodelling and inflammatory mediator balance
Packed with skin-loving Vitamin C & E and nourishing Jojoba Seed Oil, this lip treat melts onto lips to hydrate, smooth and visibly brighten in just one swipe
In SURMOUNT-2 (Fras et al., NEJM 2023), participants with type 2 diabetes and obesity achieved mean weight reductions of 12.8% to 15.7% depending on dose